Posts - Anticoagulant Therapy

May 23, 2017 3:40am
From Maureen Tacke, Idaho; Hi George, my colleagues and I enjoy the Fratsma Factor postings you send. Thank you for the work that you do instilling best practice across the nation. Each year at the PTT lot change, we redo the heparin response curve. We’ve done this to follow practices from years prior. We’ve noted in the CAP checklist that after the initial response curve, it is only necessary to compare the current lot with the new lot of PTT. We are considering changing practices, and wanted to hear your thoughts on the matter. CAP does not dictate the correlation coefficient range between lots. What would you recommend? 0.9 – 1.1? Smaller? Eventually, we’d like to change practice within our pharmacy so that they monitor patients via anti-Xa. But we are not quite to that point yet with our pharmaceutical colleagues. Thank you for your time.
Mar 23, 2017 1:08pm
A hypothetical case study: a patient whose birthdate was 9-20-1945 had ESRD and non-valvular atrial fibrillation. He had been on renal dialysis since 2011 and had been taking Coumadin since 2005, maintaining an INR
Feb 27, 2017 12:41pm
From Heather DeVries, Indiana University Health. Hi George!  We use the DDHS kit from IL on our TOP series instruments. There is a cancer patient at
1 Comment
Jan 24, 2017 3:56pm
Click or tap here for Dr. Samual Goldhaber's video clip describing the prevalence of off-label low dosing of dabigatran, rivaroxaban, and apixaban.